Supernus Pharmaceuticals Engages at Leading Health Conference

Supernus Pharmaceuticals to Participate in Major Health Conference

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), based in Rockville, Maryland, is making noteworthy strides in the biopharmaceutical sector, particularly in therapies for central nervous system (CNS) diseases. The company's President and CEO, Jack A. Khattar, is scheduled to be part of a pivotal fireside chat at the TD Cowen 45th Annual Health Care Conference.

Conference Details and Importance

This exciting event is set to take place on a Monday morning where Mr. Khattar will share insights about Supernus’s mission and future direction. Participation in such conferences is crucial as it allows the company to connect with investors, provide updates on product development, and showcase its commitment to advancing CNS treatment options.

Investor Engagement During the Conference

Investors who wish to meet with the Supernus leadership team can coordinate arrangements through the TD Cowen conference staff. Moreover, to ensure accessibility, a live audio webcast of the conversation will be made available. This allows stakeholders to participate virtually and stay informed about the company’s strategic initiatives.

Accessing the Webcast and Future Presentations

The live audio stream can be reached through Supernus's Investor Relations section on their website. Additionally, those interested will be able to access an archived version of the webcast for 60 days after the event, ensuring that no one misses out on important updates regarding Supernus's advancements in the field.

About Supernus Pharmaceuticals

Founded with a focus on developing therapeutic solutions for CNS disorders, Supernus specializes in a broad portfolio of products. These treatments effectively manage conditions such as ADHD, Parkinson's disease dyskinesia, epilepsy, and more. The company is not only committed to enhancing existing therapies but is also actively working on novel candidates aimed at addressing unmet needs in areas like depression and migraine management.

Current Product Portfolio and Developments

A standout characteristic of Supernus is its extensive experience in neuroscience, which includes state-of-the-art clinical programs. The company ensures that its portfolio is strengthened through ongoing research aiming to launch new treatments for CNS disorders currently lacking optimal solutions. As the biopharmaceutical landscape evolves, Supernus remains dedicated to confronting challenges head-on and leveraging innovative research methodologies.

Contact Information for Investors

For additional inquiries, interested parties can connect with key personnel at Supernus Pharmaceuticals. Jack A. Khattar, as well as Timothy C. Dec, the Senior Vice President and CFO, can be reached directly at their main office. Investor relation inquiries can be further directed to Peter Vozzo from ICR Healthcare for more personalized engagement.

Contact Details

Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

Frequently Asked Questions

1. What is the focus of Supernus Pharmaceuticals?

Supernus Pharmaceuticals specializes in developing treatments for central nervous system diseases.

2. When will the fireside chat take place?

The fireside chat is scheduled for a Monday morning during the TD Cowen Annual Health Care Conference.

3. How can investors access the webcast?

Investors can access the live audio webcast through Supernus's Investor Relations website.

4. Who else is involved in Supernus’s leadership?

Timothy C. Dec serves as the Senior Vice President and CFO.

5. What types of conditions does Supernus's portfolio treat?

The portfolio includes treatments for ADHD, Parkinson’s disease, epilepsy, and chronic migraine, among others.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.